Pattern of Recurrence Following Complete Resection of Esophageal Carcinoma and Factors Predictive of Recurrent Disease
|
|
- Rebecca Jefferson
- 5 years ago
- Views:
Transcription
1 1616 Pattern of Recurrence Following Complete Resection of Esophageal Carcinoma and Factors Predictive of Recurrent Disease Christophe Mariette, M.D. 1,2 Jean-Michel Balon, M.D. 1 Guillaune Piessen, M.D. 1 Sylvain Fabre, M.D. 1 Isabelle Van Seuningen, Ph.D. 2 Jean-Pierre Triboulet, M.D. 1 1 Service de chirurgie digestive et générale Hôpital Claude Huriez, CHRU, Lille, France. 2 Unité INSERM 560, Lille, France. BACKGROUND. Despite increasingly radical surgery for esophageal carcinoma, a large number of patients still experience recurrent disease soon after operation. The current study was undertaken to evaluate the pattern of recurrence after curative esophagectomy for cancer of the thoracic esophagus and to identify factors predictive of recurrent disease. METHODS. A total of 439 consecutive patients discharged from the authors institution following R0 resection between January 1982 and July 2002 were followed for evidence of recurrence over a mean interval of 37.3 (range, 1 207) months. RESULTS. Overall 1-, 3- and 5-years survival rates were 91%, 54%, and 41%, respectively. Some 230 patients (52.4%) developed proven recurrence, of whom 24 were alive and 206 were dead at the time of writing. The median time to recurrence was 12.0 (range, 6 96) months, with a median survival thereafter of 7.0 (range, 0 83) months. The pattern of recurrence was local in 12.1%, regional in 20.5% (cervical 3.6%, mediastinal 14.8%, and abdominal 2.1%), and distant in 19.8%, respectively. The overall pattern of dissemination was significantly different according to the histologic subtype (P 0.021). One hundred five (45.7%) of all recurrences occurred within 12 months of surgery, with local, regional, and distant recurrence occurring at a median of 14.0 (range, 6 77), 13.5 (range, 6 73), and 11.0 (range, 6 96) months, respectively; A factor predictive of recurrent disease was histologic tumor depth invasion (P 0.001). CONCLUSIONS. Depth of tumor invasion should be used to identify patients who will have recurrence within 12 months of operation, so that these patients may be either entered into trials of multimodality treatment or offered nonsurgical palliation. Cancer 2003;97: American Cancer Society. DOI /cncr KEYWORDS: esophageal carcinoma, surgery, recurrence, nonsurgical palliation. Address for reprints: Jean-Pierre Triboulet M.D., Service de chirurgie digestive et générale Hôpital Claude Huriez, CHRU, Place de Verdun Lille cedex France; Fax: (011) ; jp-triboulet@chru-lille.fr Received September 5, 2002; revision received November 12, 2002; accepted November 19, Carcinoma of the esophagus is often far advanced at the time of detection, and only a small number of patients are considered for curative resection and long-term survival. Resection rates range from 19% to 64% and 5-year survival from 10% to 55% depending on stage. 1 Surgical resection remains the primary treatment modality for esophageal carcinoma, as it provides sustained palliation of dysphagia and the best chance of cure. 2 Over the past 10 years advances in surgical and anaesthesic techniques, together with improvements in perioperative management, have reduced the risks of esophageal resection to an acceptable level. This reduction in the postoperative mortality rate has, however, failed to translate itself into any significant benefit in long-term survival, as large numbers of patients continue to present with recurrent disease following apparently curative surgery American Cancer Society
2 Recurrence after Radical Esophagectomy/Mariette et al TABLE 1 Distribution of Tumors According to Histologic Subtype and Site Upper third (%) Middle third (%) Lower third (%) Total (%) SCC 61 (13.8) 232 (52.8) 69 (15.7) 362 (82.5) Adenocarcinoma 1 (0.3) 13 (3.0) 63 (14.4) 77 (17.5) Total 62 (14.1) 245 (55.8) 132 (30.1) 439 (100) SCC: squamous cell carcinoma. Therefore attempts have been made to improve the outcome of surgical resection by increasing the radicality of nodal dissection or by combining surgery with other treatment modalities. Before embarking into more extensive surgical procedures or designing adjuvant therapeutic regimens, it is important to understand the causes and characteristics of recurrence after esophagectomy. The suppression of postoperative recurrences will improve the prognosis of patients with esophageal carcinoma undergoing curative resection. Thus, it is of clinical importance to predict postoperative recurrences. The current article presents the results of R0 resection for esophageal carcinoma with the aim of determining the pattern and the timing of local, regional, and distant recurrences and of assessing the factors that predict the recurrent disease. PATIENTS AND METHODS Patient Population The records of 1800 patients who underwent surgical evaluation for esophageal malignancy in our institution between January 1982 and July 2002 were reviewed. Of these, 460 consecutive patients had subtotal esophagectomy with two-field lymphadenectomy and R0 resection. Overall 30 day and in-hospital mortality rates were 2.4% (n 11) and 4.5% (n 21), respectively. Patients who had rare tumors were excluded. In the 439 patients who had undergone R0 tumor resection and who were discharged from the hospital, the median followup was 25.0 [standard deviation (SD), 35.7; range, 1 207)] months. The male to female ratio was 7.8:1 and the median age 57.6 (SD, 9.4; range 32 77) years. Squamous cell carcinoma (SCC) was the predominant histologic subtype compared with adenocarcinoma, with a ratio of 4.7:1. The majority of SCC were located at the middle third of the thoracic esophagus, whereas the majority of adenocarcinomas were located within the lower third (Table 1). Surgical Approach The detailed resection techniques have been described elsewhere. 3 Surgical resection consisted, in a transthoracic esophagectomy for tumor of the middle third or lower third of the esophagus, completed with a cervical incision for anastomosis in case of tumor of the upper third of the thoracic esophagus. The surgical approach included an abdominal lymphadenectomy and an extended en bloc mediastinal lymphadenectomy (two-field lymphadenectomy). No cervical lymphadenectomy was undertaken. Abdominal lymphadenectomy comprised en bloc removal of all lymphatic tissue in the lower posterior mediastinum, in the left and right paracardial regions, along the lesser curve, and along the left gastric artery. Lymphadenectomy of the paratracheal, carinal, and left and right bronchial nodes was performed followed by en bloc resection of the thoracic duct together with the para-aortic nodes. The nodes in the aortoplumonary window were removed, but a full dissection of the left recurrent laryngeal nerve chain was not routinely carried out. Neoadjuvant radiochemotherapy was proposed for locally advanced tumors or within the framework of therapeutic protocols. Histopathologic Assessment of the Removed Specimen and Lymph Nodes All nodal material was dissected separately from the specimen at the end of the procedure by the surgeon and analyzed according to the guidelines of the Japanese Society for Esophageal Diseases. 4 The histologic staging was based on the ptnm classification, 5 defined as follows: esophageal cancer Stage I [ptis- T1N0M0]: tumor restricted to either mucosa [ptis] or submucosa [pt1], no regional lymph node [N0], no distant metastasis [M0]; Stage IIA [pt2-t3n0m0]: tumor restricted to muscularis propria [pt2] or adventia [pt3], no regional lymph node [N0], no distant metastasis [M0]; Stage IIB: [pt1-t2n1m0]: tumor restricted to mucosa [pt1] or to muscularis propria [pt2], regional lymph node metastasis [N1], no distant metastasis [M0]; Stage III: [pt3n1 or pt4nxm0]: tumor restricted to adventia [pt3], regional lymph node metastasis [N1] or tumor invaded the neighboring structures [pt4], with or without regional lymph node metastasis [Nx], no distant metastasis [M0]. Recurrence Identification All patients surviving operation were followed until death or the time of writing at the end of the first month, at six-month intervals in years one and two, and annually thereafter. Clinical review consisted of history and abdominal examination. Abdominal ultra-
3 1618 CANCER April 1, 2003 / Volume 97 / Number 7 sonography was realized twice a year, chest X-ray, endoscopy, and indirect laryngoscopy once a year. If recurrence was suspected, patients underwent barium-swallow, ultrasonography, chest X-rays, thoracoabdominal computed tomography (CT), and endoscopic examination with biopsies. More selective investigations such as cervical ultrasonography, bone scintigraphy, and cerebral CT were carried out based on specific symptomatology, clinical examination, and biochemical profile. Follow-up was complete for all patients. By definition, the timing of recurrence was always above six months after surgery. Before six months, evidence of tumor was considered as persistent neoplastic disease. The mode of recurrence was classified into three patterns: local recurrence was defined as anastomotic recurrence; regional recurrence was defined as that occurring either in the mediastinum or upper abdomen at the site of previous esophageal resection and nodal clearance or in the cervical area where no lymphadenectomy had been performed; and distant recurrence was defined as hematogenous if it developed within a solid organ or within the peritoneal cavity. When a patient had recurrence in multiple distant organs, the initial detected organ was chosen as the recurred organ. Histologic, cytologic, or unequivocal radiologic proof was required before a diagnosis of recurrence was made. Recurrence supported by clinical impression alone was not included. Statistical Analysis The survival status of patients was ascertained in July Followup was complete for all 439 patients. Data are shown as prevalence, mean (SD), or median (SD). Comparison of continuous data between groups was done by the student t test and of ordinal data by chi-square test or Fischer exact test when appropriate. In analyzing survival time, we used the Statistical Package for Social Sciences (SPSS, Chicago, IL). The survival function was estimated by the actuarial method after excluding the postoperative deaths. The log rank test was used for comparison of survival curves. To determine predictors of distant recurrences, we used the stepwise logistic regression model, adjusting all the covariates simultaneously. The 0.1 level was defined for entry into the model. Differences were considered to be significant at 5% alpha risk. RESULTS Pattern of Recurrence At the time of writing, 264 patients had died during the follow-up period, 206 as a result of proven recurrent esophageal carcinoma and 58 from causes other than recurrence. Of the remaining 209 patients who were alive at the time of writing, 24 were known to have recurrent disease. Thus, 52.4% (230 of 439) of all patients discharged following potentially curative esophageal resection developed recurrent esophageal carcinoma. Local recurrence was recognized in 53 patients (12.1%), regional recurrence in 90 (20.5%; cervical in 16, mediastinal in 65, and abdominal in 9), and distant metastases in 87 (19.8%; liver in 35, lung in 21, bone in 18, cerebral in 7, kidney in 2, adrenal gland in 2, peritoneal in 1, and skin in 1), respectively. The patterns of recurrence according to the clinical and histopathologic factors are shown in Table 2, with a similar proportion of local, regional, and distant dissemination, except for histologic subtype and mean number of positive lymph node metastases. Distant dissemination rather than local or regional recurrences occurred more frequently with lower-third tumors (predominantly adenocarcinoma, 27.6%; 18.9% and 11.1%, respectively) whereas the opposite was true for upper or middle-third lesions (predominantly SCC, 72.4%, 81.1% and 88.9%, respectively; P 0.02). For pt1 tumors, no recurrence occurred in patients with tumor restricted to mucosa (n 12) whereas recurrence was observed in 25 (31.8%) patients with tumor restricted to submucosa. The mean number of positive lymph node metastases was significantly higher in the distant recurrence group rather than in the regional group (P 0.04). Cervical recurrence occurred in 16 patients (3.6%); all of them had SCC, six of the upper third, six of the middle third, and four of the lower third of the esophagus. Seven patients with cervical recurrence had node-positive tumors at the time of the operation. The overall incidence of recurrent disease in areas outside the operative field was 23.5%. In patients with carcinoma of the upper esophagus, recurrence was observed frequently in the neck. Conversely, in the cases with carcinoma of the lower esophagus, intraabdominal lymph node recurrence was more frequently observed than in those patients with carcinoma of other parts of the esophagus. The number of involved lymph nodes significantly associated with recurrence was found to be one or more. With regard to the distant recurrence group, there was a positive correlation between the pulmonary recurrence and either the tumor localization at the upper third of the esophagus (P 0.05), the subgroup of cervical anastomosis (P 0.01), or the SCC histologic subtype (P 0.02). Prognostic factors associated with the development of recurrent disease are shown in Table 3. There was no significant difference in the overall pattern of recurrence in relation to the level of the primary tumor. The only clinical factor associated with recurrent disease was dysphagia at the initial presentation (P
4 Recurrence after Radical Esophagectomy/Mariette et al TABLE 2 Clinical and Histopathologic Factors and Patterns of Recurrence Pattern of recurrence Local (n 53) Regional (n 90) Distant (n 87) Total (n 230) Mean (SD) age at presentation in years 58.1 (10.5) 56.7 (10.2) 56.4 (7.8) 57.6 (9.4) Gender ratio (M:F) 6.6:1 10.3:1 16.4:1 10.5:1 Location of the main tumor Upper third Middle third Lower third Weight loss 10% % Dysphagia Yes No Neoadjuvant chemoradiotherapy Yes No Anastomotic site Cervical Intrathoracic Anastomotic leak Yes No Respiratory complication Yes No Histologic subtype SCC Adenocarcinoma Differentiation Well Moderately or poorly Depth of invasion pt pt pt pt Lymph node metastasis pn pn Mean (SD) number of lymph nodes with positive metastasis 2.2 (3.3) 1.7 (2.2) 2.5 (3.4) 2.1 (3.0) ptnm stage I IIa IIb III SD: standard deviation; SCC: squamous cell carcinoma ). With regard to histopathologic factors, increased depth of tumor invasion, and the presence and the mean number of positive nodal metastases were found to correlate with an increased incidence of recurrent disease, same as the ptnm stage (P 0.001), although there was no association with the histologic subtype or histologic differentiation. Time of Recurrence Mean (SD) time to recurrence after operation was 17.8 (15.3; range, 6 96) months, with 45.7% (105 of 230) of all recurrences developing within 12 months of operation (43.4%, 40.0%, and 52.9% for local, regional, and distant recurrences, respectively). The median delay before recurrence was 12.0 months, and the median time between recurrence and death was 7.0 months. The median (SD) time to local recurrence was 14.0 (13.5; range, 6 77) months, the median (SD) time to regional recurrence was 13.5 (14.2; range, 6 73) months, and the median (SD) time for distant recurrence was 11.0 (17.5; range, 6 96) months. Median time to recurrence was shorter in the distant recurrence group compared with local or regional recurrence groups (P 0.04). Ninety percent of recurrences occurred before the 38th month. In the recurrence group, the mean (SD) recurrence times of each ptnm stage were 12.9 (17.0) months in Stage I, 11.8 (13.3) months in Stage IIA, 7.0 (5.6) months in Stage IIB, and 8.1 (8.8) months in Stage III. Mean recurrence times were significantly lower for Stage III compared with Stages I or IIA (P 0.04 and P 0.03, respectively) and for Stage IIB compared with Stage IIA (P 0.04). Even
5 1620 CANCER April 1, 2003 / Volume 97 / Number 7 TABLE 3 Prognostic Factors Associated with the Development of Recurrent Disease Recurrence (n 230) No recurrence (n 209) P Mean (SD) age at presentation 56.9 (9.4) 58.3 (9.3) Gender ratio (M:F) Location of the main tumor Upper third Middle third Lower third Weight loss 10% % Dysphagia Yes No Neoadjuvant chemoradiotherapy Yes No Anastomotic site Cervical Intrathoracic Anastomotic leak Yes No Respiratory complication Yes No Histologic subtype SCC Adenocarcinoma Differentiation Well Moderately or poorly Depth of invasion pt pt pt pt4 1 2 Lymph node metastasis pn pn Mean (SD) number of lymph node with positive metastasis 2.1 (3.0) 0.9 (1.7) ptnm stage I IIa IIb III SD: standard deviation; SCC: squamous cell carcinoma. with Stage I esophageal carcinoma, recurrence within 12 months was recognized in 17 of 30 cases, and it was also observed in 37 of 59 cases in Stage IIA. Distant recurrence within 12 months was observed in 4 and 10 patients with Stage I and IIA, respectively. Treatment of Recurrent Disease Thirty-five patients (24.5%) with local or regional recurrence had no specific treatment other than pain control. Patients with dysphagia due to anastomotic, conduit, or hiatal recurrence were palliated with dilatation and endoprothesis insertion with or without radiotherapy, depending on their general condition. The majority of patients with distant organ metastasis received no definitive therapy other than symptomatic relief. Adjuvant therapy for recurrent disease was performed in 28 of 115 patients (24.3%) who had received neoadjuvant radiochemotherapy. Twenty-six patients (46.4%) with liver or pulmonary metastases received palliative chemotherapy with 5-fluorouracil and cisplatin, six (33.3%) with bone metastases underwent palliative radiotherapy or orthopaedic fixation, and two (28.6%) with cerebral localization underwent surgery with external radiotherapy. No survival advantage was observed in patients who were selected for interventional therapy compared with those who had symptomatic treatment alone. Recurrent laryngeal nerve palsies resulting from cervical recurrence were treated with Teflon injection and later with thyroplasty. Patients with isolated asymptomatic recurrent
6 Recurrence after Radical Esophagectomy/Mariette et al TABLE 4 Multivariate Analysis: Predictive Factors of Recurrent Disease Variables P X2 Relative risk 95% confidence interval Gender Dysphagia Depth of tumor invasion Lymph node metastasis ptnm stage FIGURE 1. Overall survival following discharge for 439 patients undergoing R0 resection for esophageal carcinoma according to the TNM stage. The number of subjects at risk at each interval is shown in the table at the bottom of the graph. cervical node disease had ipsilateral radical cervical lymph node clearance and postoperative radiotherapy. Survival and Predictive Factors of Recurrence The median follow-up interval was 25.0 (35.7; range, 1 207) months. The median (SD) survival of patients was 38.6 (3.2) months and median (SD) time free of disease was 37.0 (2.5) months. The overall and disease free 1-, 3-, and 5-year survival rates were 91%, 54%, 41%, and 91%, 53%, 37%, respectively. Stratification of recurrence free survival according to the ptnm staging system confirmed a significantly worse survival for more advanced tumors (Fig. 1). Median (SD) survival following the detection of recurrent esophageal carcinoma was 7.0 (0.5) months and was significantly longer for regional dissemination [7.0 (0.8) months] than for local [5.0 (1.0) months] or distant [5.0 (0.9) months] recurrence (P 0.01). Median survival (SD) in patients with cervical recurrence was 26 (7.3) months and was significantly longer than in those with recurrence at other sites (P 0.049). There was no difference in median of disease-free interval between SCC and adenocarcinoma (38.0 and 36.0 months, respectively, P 0.19), or between upper-third, middle-third, and lower-third lesions (38.0, 37.0, and 37.0 months, respectively, P 0.90). The only predictive factor of recurrent disease, obtained by multivariate analysis, was the depth of the tumor invasion on the histologic assessment (pt) (X , risk ratio 1.9, 95% confidence interval [CI] , P 0.001; Table 4). We did not find any significant factor predictive of recurrence for the either subgroups, local, regional, or distant recurrence, neither for recurrence occurring within 12 months after curative surgery. DISCUSSION At a median follow-up of 37.3 months, recurrent esophageal carcinoma had developed in almost half of the patients who underwent an apparently curative resection, with an overall 5-year survival rate of only 41%. These dismal results occurred in an already highly selected patient group who had been staged having localized and resectable tumors. The treatment of recurrent disease is disappointing, and there is no evidence that currently available treatment can prolong survival. 6 The results of the current study suggest that patients at high risk of developing recurrence need to be identified in the preoperative staging process, since more than 50% of all recurrences occurred within 12 months after surgery, either in local, regional, or distant sites. Tumor depth invasion was the only factor predictive of recurrent disease (P 0.001). With the aim of decreased incidence of recurrent disease in esophageal carcinoma, many approaches were proposed. Early diagnosis is essential to improve the curability and the resectability of this cancer. While it is evident from the stage-specific survival figure presented here that early tumors (pt1) are associated with a low incidence of recurrence and a significant survival advantage, they are found in only a few patients undergoing surgery (33.5%). Even if the primary tumor is limited to the submucosal layer, it may proceed to lymph node 6 or distant metastases (31.8% in the current study). Moreover, pretherapeutic
7 1622 CANCER April 1, 2003 / Volume 97 / Number 7 exploration is hampered by the difficulty in determining exactly the tumoral stage. Like other authors, 7 pt classification seems to appear to us as an important prognostic factor of recurrent disease, with increased prevalence of lymph node metastases with increasing tumor depth. 8 Instead, strategies aimed at decreasing the recurrence rate and improving survival must continue to focus on the majority of patients who present advanced esophageal carcinoma. Radical lymphadenectomies, such as en bloc esophagectomy 8 12 and three-field dissection, 7,13 have been developed hoping that meticulous nodal dissection would improve pathologic tumor staging, enhance local control, and provide some survival benefit in terms of delay to recurrence and even long-term cure. Dresner et al. 14 have reported a 21% local recurrence rate following radical resection for middle-third and lower-third tumors, which is lower than that described in other series where no formal lymphadenectomy was performed. 15 There are some conflicting reports suggesting that lymphadenectomy confers no survival benefit. 16 Furthermore, despite the strong association between nodal disease and tumor recurrence, in the current study, some node-positive patients were long-term survivors, with 5-year survival rates of 39% and 19% for Stages IIB and III tumors, respectively. In an effort to improve the results of surgery still further, Japanese surgeons have advocated the addition of cervical lymphadenectomy to conventional thoracoabdominal lymph node dissection. In a recent prospective study, 17 an overall rate of 36% for cervical nodal disease was documented by three-field nodal dissection, with no statistically significant differences in overall survival. In the current series, isolated cervical recurrence occurred in only 16 patients (3.6%), suggesting a much lower incidence of positive cervical nodes than described previously. 18,19 Any potential benefit from cervical lymphadenectomy must be balanced against the additional morbidity and mortality, particularly related to laryngeal nerve damage. 17 Alternative strategies to decrease recurrence and improve survival have therefore turned away from increasingly radical surgery and focused more on multimodality therapy. With regard to distant recurrence, its frequency after curative esophagectomy was similar compared with regional recurrence (37.8% vs 39.1% in the current experience). However, the median time for distant recurrence is significantly shorter than that of regional recurrence (11.0 and 13.5 months, respectively). These findings suggest that microscopic metastasis often already occurs at the time of operation or that metastatic lesions show an extremely rapid growth after operation. 15 Moreover, it suggests that lymph node recurrence did not primarily occur before distant dissemination, as suggested by some authors, who think that lymphatic and hematogenic extension occur independently. 20,21 This could explain the 40.4% of patients without any lymph node metastases who developed recurrence in the current study. Indeed, one recent prospective study in which trephine was performed in patients with operable esophageal carcinoma showed micrometastases in 88% of rib and 15% of iliac bone marrow aspirates. 22 Furthermore, distant recurrence within 12 months also occurred even in the cases with early stage carcinoma, with 4 and 10 patients with Stages I and IIA esophageal carcinoma, respectively, in the current series. Surgery as a single modality therapy can be considered only as a local treatment. Systemic treatment of potentially disseminated disease may be accomplished by the use of chemotherapy, particularly if administered in the neoadjuvant setting. In the current series we found no benefit in neoadjuvant treatment regarding recurrence (P 0.34). Results of randomized controlled trials performed to date are conflicting and open to criticism. So far, six reported randomized trials comparing preoperative combined chemotherapy and radiotherapy followed by surgery with surgery alone in resectable esophageal carcinoma have been reported. When using neoadjuvant chemoradiotherapy, only the Walsh et al. trial 23 showed an improvement in survival, and only one study has suggested an improvement of survival 29 when using neoadjuvant chemotherapy. Finally, two randomized trials, 30,31 in which postoperative chemotherapy was used, failed to show an improvement. However, the use of postoperative chemotherapy in patients at high risk of recurrence is still in research stages in Europe. The high incidence, the shorter median time to recurrence, and the predominant lower-third esophageal tumors in the distant recurrence group suggest genuine biologic differences between adenocarcinoma and SCC. There are two groups of patients whom we must try to identify. They are those who already have metastatic disease at the time of diagnosis but who are not being identified by current staging techniques and those who have micrometastases. The former group are unlikely to be cured by surgery and would die early without benefiting from radical treatment. In such cases, consideration should be given to nonoperative treatment. For the latter group inclusion in trials of systemic, neoadjuvant therapy should be considered. Moreover, other histologic or biologic tools should be used to select patients who will benefit from this strategy Despite radical surgery and in some case preoperative chemoradiation, patient death is often related to local or regional recurrence and distant dissemina-
8 Recurrence after Radical Esophagectomy/Mariette et al tion. Patients at high risk of recurrence need to be identified accurately before operation so that they may be offered entry into trials of multimodality therapy or alternatively considered for nonsurgical palliation. Further oncologic research is needed to predict distant recurrence. REFERENCES 1. Mariette C, Fabre S, Balon JM, Finzi L, Triboulet JP. Factors predictive of complete resection of operable esophageal cancer: review of 746 patients. Gastroenterol Clin Biol. 2002; 26: Triboulet JP, Mariette C, Chevalier D, Amrouni H. Surgical management of carcinoma of the hypopharynx and cervical esophagus: analysis of 209 cases. Arch Surg. 2001;136: Mariette C, Castel B, Toursel H, Fabre S, Balon JM, Triboulet JP. Surgical management of and long-term survival after adenocarcinoma of the cardia. Br J Surg. 2002;89: Japanese Society for Esophageal Diseases. Guidelines for the clinical and pathologic studies for carcinoma of the esophagus. Jpn J Surg. 1976;6: Sobon LH, Wittekind C, editors. UICC TNM classification of malignant tumors, 5th ed. New York: Wiley-Liss, Raoul JL, Le Prise E, Meunier B, et al. Combined radiochemotherapy for postoperative recurrence of oesophageal cancer. Gut. 1995;37: Bhansali MS, Fujita H, Kakegawa T, et al. Pattern of recurrence after extended radical esophagectomy with three-field lymph node dissection for squamous cell carcinoma in the thoracic esophagus. World J Surg. 1997;21: Hagen JA, DeMeester SR, Peters JH, Chandrasoma P, De- Meester TR. Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Ann Surg. 2001;234: Collard JM, Otte JB, Fiasse R, et al. Skeletonizing en bloc esophagectomy for cancer. Ann Surg. 2001;234: Lerut T, De Leyn P, Coosemans W, Van Raemdonck D, Scheys I, LeSaffre E. Surgical strategies in esophageal carcinoma with emphasis on radical lymphadenectomy. Ann Surg. 1992;216: Holscher AH, Bollschweiler E, Bumm R, Bartels H, Hofler H, Siewert JR. Prognostic factors of resected adenocarcinoma of the esophagus. Surgery. 1995;118: Collard JM. Exclusive radical surgery for esophageal adenocarcinoma. Cancer. 2001;91: Akiyama H, Tsurumaru M, Udagawa H, Kajiyama Y. Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg. 1994;220: Dresner SM, Griffin SM. Pattern of recurrence following radical oesophagectomy with two-field lymphadenectomy. Br J Surg. 2000;87: Van Lanschot JJ, Tilanus HW, Voormolen MH, van Deelen RA. Recurrence pattern of oesophageal carcinoma after limited resection does not support wide local excision with extensive lymph node dissection. Br J Surg. 1994;81: Hulscher JB, van Sandick JW, Tijssen JG, Obertop H, van Lanschot JJ. The recurrence pattern of esophageal carcinoma after transhiatal resection. J Am Coll Surg. 2000;19: Altorki N, Kent M, Ferrara C, Port J. Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg. 2002;236: Kato H, Watanabe H, Tachimori Y, Iizuka T. Evaluation of neck lymph node dissection for thoracic esophageal carcinoma. Ann Thorac Surg. 1991;51: Isono K, Sato H, Nakayama K. Results of a nationwide study on the three-field lymph node dissection of esophageal cancer. Oncology. 1991;48: Morita M, Kuwano H, Ohno S, Furusawa M, Sugimachi K. Characteristics and sequence of the recurrent patterns after curative esophagectomy for squamous cell carcinoma. Surgery. 1994;116: Matsubara T, Ueda M, Kaisaki S, et al. Localization of initial lymph node metastasis from carcinoma of the thoracic esophagus. Cancer. 2000;89: O sullivan GC, Sheehan D, Clarke A, et al. Micrometastases in esophagogastric cancer: high detection rate in resected rib segments. Gastroenterology. 1999;116: Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996; 335: Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997; 337: Le Prise E, Etienne PL, Meunier B, et al. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer. 1994;73: Nygaard K, Hagen S, Hansen HS, et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg. 1992;16: Apinop C, Puttisak P, Preecha N. A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology. 1994;41: Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19: Medical Research Council. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002;359: Pouliquen X, Levard H, Hay JM, McGee K, Fingerhut A, Langlois-Zantin O. 5-Fluorouracil and cisplatin therapy after palliative surgical resection of squamous cell carcinoma of the esophagus. A multicenter randomized trial. French Associations for Surgical Research. Ann Surg. 1996;223: Ando N, Iizuka T, Kakegawa T, et al. A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study. J Thorac Cardiovasc Surg. 1997; 114: Brucher BL, Stein HJ, Werner M, Siewert JR. Lymphatic vessel invasion is an independent prognostic factor in patients with a primary resected tumor with esophageal squamous cell carcinoma. Cancer. 2001;92: Tajima Y, Nakanishi Y, Ochiai A, et al. Histopathologic findings predicting lymph node metastasis and prognosis of patients with superficial esophageal carcinoma: analysis of 240 surgically resected tumors. Cancer. 2000;88: Kawaguchi H, Ohno S, Miyazaki M, et al. CYFRA 21-1 determination in patients with esophageal squamous cell carcinoma: clinical utility for detection of recurrences. Cancer. 2000;89:
A Proposed Strategy for Treatment of Superficial Carcinoma. in the Thoracic Esophagus Based on an Analysis. of Lymph Node Metastasis
Kitakanto Med J 2002 ; 52 : 189-193 189 A Proposed Strategy for Treatment of Superficial Carcinoma in the Thoracic Esophagus Based on an Analysis of Lymph Node Metastasis Susumu Kawate,' Susumu Ohwada,'
More informationLymph node metastasis is one of the most important prognostic
ORIGINAL ARTICLE Comparison of Survival and Recurrence Pattern Between Two-Field and Three-Field Lymph Node Dissections for Upper Thoracic Esophageal Squamous Cell Carcinoma Young Mog Shim, MD, Hong Kwan
More informationInvasion of neighboring tissues (that is, trachea, aorta,
Factors Predictive of Complete Resection of Operable Esophageal Cancer: A Prospective Study Christophe Mariette, MD, Laetitia Finzi, MD, Sylvain Fabre, MD, Jean-Michel Balon, MD, Isabelle Van Seuningen,
More informationOCCULT CERVICAL NODAL METASTASIS IN ESOPHAGEAL CANCER: PRELIMINARY RESULTS OF THREE-FIELD LYMPHADENECTOMY
OCCULT CERVICAL NODAL METASTASIS IN ESOPHAGEAL CANCER: PRELIMINARY RESULTS OF THREE-FIELD LYMPHADENECTOMY Nasser K. Altorki, MD David B. Skinner, MD The extent of lymphadenectomy for carcinoma of the thoracic
More informationComparison of Surgical Management of Thoracic Esophageal Carcinoma Between Two Referral Centers in Japan and China
Jpn J Clin Oncol 2001;31(5)203 208 Comparison of Surgical Management of Thoracic Esophageal Carcinoma Between Two Referral Centers in Japan and China Wentao Fang 1,HoichiKato 2, Wenhu Chen 1,YujiTachimori
More informationAlthough esophagectomy remains the standard of care for esophageal
Keresztes et al General Thoracic Surgery Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: Results of a phase II trial R. S. Keresztes, MD J. L. Port, MD M. W. Pasmantier,
More informationCarcinogenesis and treatment of adenocarcinoma of the oesophagus and gastric cardia Hulscher, J.B.F.
UvA-DARE (Digital Academic Repository) Carcinogenesis and treatment of adenocarcinoma of the oesophagus and gastric cardia Hulscher, J.B.F. Link to publication Citation for published version (APA): Hulscher,
More informationEsophageal cancer is a significant health hazard for
Postoperative Radiotherapy Improved Survival of Poor Prognostic Squamous Cell Carcinoma Esophagus GENERAL THORACIC Junqiang Chen, MD, Ji Zhu, MD, Jianji Pan, MD, Kunshou Zhu, MD, Xiongwei Zheng, MD, Mingqiang
More informationClassification of Recurrent Esophageal Cancer after Radical Esophagectomy with Two- or Three-field Lymphadenectomy
Classification of Recurrent Esophageal Cancer after Radical Esophagectomy with Two- or Three-field Lymphadenectomy HIROYUKI KATO, MINORU FUKUCHI, TATSUYA MIYAZAKI, MASANOBU NAKAJIMA, HITOSHI KIMURA, AHMAD
More informationClinicopathologic and prognostic factors of young and elderly patients with esophageal adenocarcinoma: is there really a difference?
Diseases of the Esophagus (2008) 21, 596 600 DOI: 10.1111/j.1442-2050.2008.00817.x Original article Clinicopathologic and prognostic factors of young and elderly patients with esophageal adenocarcinoma:
More informationSurgical strategies in esophageal cancer
Gastro-Conference Berlin 2005 October 1-2, 2005 Surgical strategies in esophageal cancer J. Rüdiger Siewert Department of Surgery, Klinikum rechts der Isar Technische Universität München Esophageal Cancer
More informationEsophageal carcinoma is one of the most tedious
Subcarinal Node Metastasis in Thoracic Esophageal Squamous Cell Carcinoma Jingeng Liu, MD,* YiHu,MD,* Xuan Xie, MD, and Jianhua Fu, MD Department of Thoracic Oncology, Cancer Center, Sun Yat-sen University,
More informationControversies in management of squamous esophageal cancer
2015.06.12 12.47.48 Page 4(1) IS-1 Controversies in management of squamous esophageal cancer C S Pramesh Thoracic Surgery, Department of Surgical Oncology, Tata Memorial Centre, India In Asia, squamous
More informationEfficacy of intraoperative radiotherapy targeted to the abdominal lymph node area in patients with esophageal carcinoma
Journal of Radiation Research Advance Access published August 7, 2012 Journal of Radiation Research, 2012, 00, 1 10 doi: 10.1093/jrr/rrs045 Regular Paper Efficacy of intraoperative radiotherapy targeted
More informationCase Scenario 1. The patient has now completed his neoadjuvant chemoradiation and has been cleared for surgery.
Case Scenario 1 July 10, 2010 A 67-year-old male with squamous cell carcinoma of the mid thoracic esophagus presents for surgical resection. The patient has completed preoperative chemoradiation. This
More informationTranshiatal Esophagectomy: Lower Mortality, Diminished Morbidity, Equal Effectiveness
Transhiatal Esophagectomy: Lower Mortality, Diminished Morbidity, Equal Effectiveness Sunil Malhotra, M.D. Department of Surgery University of Colorado Resident Debate April 30, 2007 Esophageal Cancer
More informationThree-Field Lymph Node Dissection for Squamous Cell and Adenocarcinoma of the Esophagus
ANNALS OF SURGERY Vol. 236, No. 2, 177 183 2002 Lippincott Williams & Wilkins, Inc. Three-Field Lymph Node Dissection for Squamous Cell and Adenocarcinoma of the Esophagus Nasser Altorki, MD, Michael Kent,
More informationDetermining the optimal number of lymph nodes harvested during esophagectomy
Original Article Determining the optimal number of lymph nodes harvested during esophagectomy Khaldoun Almhanna, Jill Weber, Ravi Shridhar, Sarah Hoffe, Jonathan Strosberg, Kenneth Meredith Department
More informationESOPHAGEAL CANCER. Dr. Paul Gardiner December 17, 2002 Discipline of Surgery Rounds
ESOPHAGEAL CANCER Dr. Paul Gardiner December 17, 2002 Discipline of Surgery Rounds ESOPHAGEAL CANCER I. EPIDEMIOLOGY INCIDENCE, DIAGNOSIS & STAGING II. TREATMENT OPTIONS Current role of induction therapies
More informationEsophageal cancer is one of the most malignant tumors,
Patterns of Lymph Node Metastasis and Survival for Upper Esophageal Squamous Cell Carcinoma Hee-Jin Jang, MD,* Hyun-Sung Lee, MD, PhD,* Moon Soo Kim, MD, Jong Mog Lee, MD, and Jae Ill Zo, MD, PhD Center
More informationDetermining the Optimal Surgical Approach to Esophageal Cancer
Determining the Optimal Surgical Approach to Esophageal Cancer Amit Bhargava, MD Attending Thoracic Surgeon Department of Cardiovascular and Thoracic Surgery Open Esophagectomy versus Minimally Invasive
More informationSETTING Fudan University Shanghai Cancer Center. RESPONSIBLE PARTY Haiquan Chen MD.
OFFICIAL TITLE A Phase Ⅲ Study of Left Side Thoracotomy Approach (SweetProcedure) Versus Right Side Thoracotomy Plus Midline Laparotomy Approach (Ivor-Lewis Procedure) Esophagectomy in Middle or Lower
More informationImpact of esophageal cancer staging on overall survival and disease-free survival based on the 2010 AJCC classification by lymph nodes
Journal of Radiation Research, 2013, 54, 307 314 doi: 10.1093/jrr/rrs096 Advance Access Publication 2 November 2012 Impact of esophageal cancer staging on overall survival and disease-free survival based
More informationLymph node invasion might have more prognostic impact than R status in advanced esophageal adenocarcinoma
The American Journal of Surgery (2013) 205, 711-717 Clinical Surgery Lymph node invasion might have more prognostic impact than R status in advanced esophageal adenocarcinoma Magali Cabau, M.D. a, Guillaume
More informationManagement of Esophageal Cancer: Evidence Based Review of Current Guidelines. Madhuri Rao, MD PGY-5 SUNY Downstate Medical Center
Management of Esophageal Cancer: Evidence Based Review of Current Guidelines Madhuri Rao, MD PGY-5 SUNY Downstate Medical Center Case Presentation 68 y/o male PMH: NIDDM, HTN, hyperlipidemia, CAD s/p stents,
More informationLymph node dissection for lung cancer is both an old
LOBE-SPECIFIC EXTENT OF SYSTEMATIC LYMPH NODE DISSECTION FOR NON SMALL CELL LUNG CARCINOMAS ACCORDING TO A RETROSPECTIVE STUDY OF METASTASIS AND PROGNOSIS Hisao Asamura, MD Haruhiko Nakayama, MD Haruhiko
More informationEsophageal cancer: Biology, natural history, staging and therapeutic options
EGEUS 2nd Meeting Esophageal cancer: Biology, natural history, staging and therapeutic options Michael Bau Mortensen MD, Ph.D. Associate Professor of Surgery Centre for Surgical Ultrasound, Upper GI Section,
More informationCHEMOTHERAPY FOLLOWED BY SURGERY VS. SURGERY ALONE FOR LOCALIZED ESOPHAGEAL CANCER
CHEMOTHERAPY FOLLOWED BY VS. ALONE FOR LOCALIZED ESOPHAGEAL CANCER CHEMOTHERAPY FOLLOWED BY COMPARED WITH ALONE FOR LOCALIZED ESOPHAGEAL CANCER DAVID P. KELSEN, M.D., ROBERT GINSBERG, M.D., THOMAS F. PAJAK,
More informationOncologist. The. Multimodality Therapy for Esophageal Cancer J.R. SIEWERT, H.J. STEIN, U. FINK ABSTRACT. Meet The Professor
The Oncologist Meet The Professor Multimodality Therapy for Esophageal Cancer J.R. SIEWERT, H.J. STEIN, U. FINK Chirurgische Klinik und Poliklinik, Klinikum rechts der Isar der TU München, München, Germany
More informationGeneral introduction and outline of thesis
General introduction and outline of thesis General introduction and outline of thesis 11 GENERAL INTRODUCTION AND OUTLINE OF THESIS The incidence of esophageal cancer is increasing in the western world.
More informationDelay in Diagnostic Workup and Treatment of Esophageal Cancer
J Gastrointest Surg (2010) 14:476 483 DOI 10.1007/s11605-009-1109-y ORIGINAL ARTICLE Delay in Diagnostic Workup and Treatment of Esophageal Cancer Brechtje A. Grotenhuis & Pieter van Hagen & Bas P. L.
More informationPrognosis and Treatment After Diagnosis of Recurrent Esophageal Carcinoma Following Esophagectomy with Curative Intent
Ann Surg Oncol () :S9 S DOI.4/s44--484- ORIGINAL ARTICLE THORACIC ONCOLOGY Prognosis and Treatment After Diagnosis of Recurrent Esophageal Carcinoma Following Esophagectomy with Curative Intent K. Parry,
More informationThe Learning Curve for Minimally Invasive Esophagectomy
The Learning Curve for Minimally Invasive Esophagectomy AATS Focus on Thoracic Surgery Mastering Surgical Innovation Las Vegas Nevada Oct. 27-28 2017 Scott J Swanson, M.D. Professor of Surgery Harvard
More informationClinicopathological Characteristics and Outcome Indicators of Stage II Gastric Cancer According to the Japanese Classification of Gastric Cancer
Clinicopathological Characteristics and Outcome Indicators of Stage II Gastric Cancer According to the Japanese Classification of Gastric Cancer HITOSHI OJIMA 1, KEN-ICHIRO ARAKI 1, TOSHIHIDE KATO 1, KAORI
More informationINTRODUCTION. Jpn J Clin Oncol 2006;36(12) doi: /jjco/hyl105
The Range of Tumor Extension Should Have Precedence over the Location of the Deepest Tumor Center in Determining the Regional Lymph Node Grouping for Widely Extending Esophageal Carcinomas Jpn J Clin Oncol
More informationThe incidence of esophageal carcinoma has increased
The Best Operation for Esophageal Cancer? Arjun Pennathur, MD, Jie Zhang, MD, Haiquan Chen, MD, and James D. Luketich, MD Heart, Lung, and Esophageal Surgery Institute, University of Pittsburgh Medical
More informationAlthough the international TNM classification system
Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru
More informationRadiation Therapy for Recurrent Esophageal Cancer after Surgery: Clinical Results and Prognostic Factors
Radiation Therapy for Recurrent Esophageal Cancer after Surgery: Clinical Results and Prognostic Factors Yoshiyuki Shioyama 1, Katsumasa Nakamura 1, Saiji Ohga 1, Satoshi Nomoto 1, Tomonari Sasaki 1, Toshihiro
More informationXiang Hu*, Liang Cao*, Yi Yu. Introduction
Original Article Prognostic prediction in gastric cancer patients without serosal invasion: comparative study between UICC 7 th edition and JCGS 13 th edition N-classification systems Xiang Hu*, Liang
More information7/20/2017. Esophageal Cancer: A Less Common But Deadly Cancer. Objectives. Disclosure Statement NYNPA Conference October Saratoga New York
Esophageal Cancer: A Less Common But Deadly Cancer 2017 NYNPA Conference October 18-22 Saratoga New York Mary McGreal DNP, RN, ANP-C, CCRN, CMC, Adjunct Professor at Stony Brook University School of Nursing
More informationChen et al. BMC Surgery 2014, 14:110
Chen et al. BMC Surgery 2014, 14:110 RESEARCH ARTICLE Open Access Cervical lymph node metastasis classified as regional nodal staging in thoracic esophageal squamous cell carcinoma after radical esophagectomy
More informationThe CROSS road in neoadjuvant therapy for esophageal cancer: long-term results of CROSS trial
Editorial The CROSS road in neoadjuvant therapy for esophageal cancer: long-term results of CROSS trial Ian Wong, Simon Law Division of Esophageal and Upper Gastrointestinal Surgery, Department of Surgery,
More informationOutcomes After Esophagectomy: A Ten-Year Prospective Cohort
J. MAXWELL CHAMBERLAIN MEMORIAL PAPER Outcomes After Esophagectomy: A Ten-Year Prospective Cohort Stephen H. Bailey, MD, David A. Bull, MD, David H. Harpole, MD, Jeffrey J. Rentz, MD, Leigh A. Neumayer,
More informationThe Royal Marsden. Surgery for Gastric and GE Junction Cancer: primary palliative when and where? William Allum Consultant Surgeon
The Royal Marsden Surgery for Gastric and GE Junction Cancer: primary palliative when and where? William Allum Consultant Surgeon Any surgeon can cure Surgeon - dependent No surgeon can cure EMR D2 GASTRECTOMY
More informationMinimally Invasive Esophagectomy- Valuable. Jayer Chung, MD University of Colorado Health Sciences Center December 11, 2006
Minimally Invasive Esophagectomy- Valuable Jayer Chung, MD University of Colorado Health Sciences Center December 11, 2006 Overview Esophageal carcinoma What is minimally invasive esophagectomy (MIE)?
More informationThe prognosis for patients with esophageal cancer is poor.
ORIGINAL ARTICLE A Phase II Study of Paclitaxel, Carboplatin, and Radiation with or without Surgery for Esophageal Cancer Henry Wang, MD, Janice Ryu, MD, David Gandara, MD, Richard J. Bold, MD, Shiro Urayama,
More informationPrognostic factors in patients with thoracic esophageal carcinoma staged pt 1-4a N 0 M 0 undergone esophagectomy with three-field lymphadenectomy
Original Article Page 1 of 7 Prognostic factors in patients with thoracic esophageal carcinoma staged pt 1-4a N 0 M 0 undergone esophagectomy with three-field lymphadenectomy Xiaohui Chen 1, Junqiang Chen
More informationPOSTOPERATIVE COMPLICATIONS OF TRANSTHORACIC ESOPHAGECTOMY FOR ESOPHAGEAL CARCINOMA
International International Multidisciplinary Multidisciplinary e Journal/ e-journal Dr. A. Razaque Shaikh, Dr. Khenpal Das, Dr Shahida Khatoon ISSN 2277. (133-140) - 4262 POSTOPERATIVE COMPLICATIONS OF
More informationCharacteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases Mei Li & Zhi-xiong Lin Department of Radiation
More informationManagement of oesophageal carcinoma
THEME GI malignancies Management of oesophageal carcinoma Sean Mackay MD, FRACS, is an upper GIT and hepatobiliary surgeon, Peter MacCallum Cancer Institute, St Vincent s and Box Hill Hospitals, Victoria,
More informationMinimally Invasive Esophagectomy: OVERRATED!!! Sagar Damle UCHSC December 11, 2006
Minimally Invasive Esophagectomy: OVERRATED!!! Sagar Damle UCHSC December 11, 2006 Esophageal Cancer - Est. 15,000 cases in 2006 - Est. 14,000 deaths - Overall 5-year survival: 15.6% - 33.6 % for local
More informationEsophageal Cancer. Wesley A. Papenfuss MD FACS Surgical Oncology Aurora Cancer Care. David Demos MD Thoracic Surgery Aurora Cancer Care
Esophageal Cancer Wesley A. Papenfuss MD FACS Surgical Oncology Aurora Cancer Care David Demos MD Thoracic Surgery Aurora Cancer Care No Disclosures Learning Objectives Review the classification scheme
More informationMetachronous pulmonary metastasis after radical esophagectomy for esophageal cancer: prognosis and outcome
Takemura et al. Journal of Cardiothoracic Surgery 2012, 7:103 RESEARCH ARTICLE Open Access Metachronous pulmonary metastasis after radical esophagectomy for esophageal cancer: prognosis and outcome Masashi
More informationClinicopathologic Characteristics and Prognosis of Gastric Cancer in Young Patients
Yonago Acta medica 2012;55:57 61 Clinicopathologic Characteristics and Prognosis of Gastric Cancer in Young Patients Hiroaki Saito, Seigo Takaya, Yoji Fukumoto, Tomohiro Osaki, Shigeru Tatebe and Masahide
More informationSuccessful Resection of Esophageal Carcinoma Associated with Double Aortic Arch: A Case Report
Successful Resection of Esophageal Carcinoma Associated with Double Aortic Arch: A Case Report NAOSHI KUBO 1, MASAICHI OHIRA 1, YOSHITO YAMASHITA 2, KATSUNOBU SAKURAI 1, HIROAKI TANAKA 1, KAZUYA MUGURUMA
More informationMultivariate analysis of clinical, operative and pathologic features of esophageal cancer: who needs adjuvant therapy?
Diseases of the Esophagus (2002) 15, 155 159 Ó 2002 ISDE/Blackwell Publishing Asia Original article Multivariate analysis of clinical, operative and pathologic features of esophageal cancer: who needs
More informationPrognostic Factors for the Survival of Patients with Esophageal Carcinoma in the U.S.
1434 Prognostic Factors for the Survival of Patients with Esophageal Carcinoma in the U.S. The Importance of Tumor Length and Lymph Node Status Mohamad A. Eloubeidi, M.D., M.H.S. 1,2 Renee Desmond, Ph.D.
More informationGTS. Abbreviation and Acronym UICC ¼ Union for International Cancer Control
General Thoracic Surgery Tachimori et al Supraclavicular node metastasis from thoracic esophageal carcinoma: A surgical series from a Japanese multi-institutional nationwide registry of esophageal cancer
More informationSignificance of the lymph nodes in the 7th station in rational dissection for metastasis of distal gastric cancer with different T categories
Original Article Significance of the lymph nodes in the 7th station in rational dissection for metastasis of distal gastric cancer with different T categories Wu Song, Yulong He, Shaochuan Wang, Weiling
More informationLong-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules
Long-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules YASUHIRO ITO, TAKUYA HIGASHIYAMA, YUUKI TAKAMURA, AKIHIRO MIYA, KAORU KOBAYASHI, FUMIO MATSUZUKA, KANJI KUMA
More informationDi Lu 1#, Xiguang Liu 1#, Mei Li 1#, Siyang Feng 1#, Xiaoying Dong 1, Xuezhou Yu 2, Hua Wu 1, Gang Xiong 1, Ruijun Cai 1, Guoxin Li 3, Kaican Cai 1
Case Report Three-port mediastino-laparoscopic esophagectomy (TPMLE) for an 81-year-old female with early-staged esophageal cancer: a case report of combining single-port mediastinoscopic esophagectomy
More informationReceived 16 June 2001; received in revised form 13 September 2001; accepted 13 September 2001
European Journal of Cardio-thoracic Surgery 20 (2001) 1089 1094 www.elsevier.com/locate/ejcts Clinicopathologic characteristics and survival of patients with clinical Stage I squamous cell carcinomas of
More informationTowards a more personalized approach in the treatment of esophageal cancer focusing on predictive factors in response to chemoradiation Wang, Da
University of Groningen Towards a more personalized approach in the treatment of esophageal cancer focusing on predictive factors in response to chemoradiation Wang, Da IMPORTANT NOTE: You are advised
More informationMUSCLE - INVASIVE AND METASTATIC BLADDER CANCER
10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg
More informationAliu Sanni MD SUNY Downstate Medical Center August 16, 2012
Aliu Sanni MD SUNY Downstate Medical Center August 16, 2012 Case Presentation 60yr old AAF with PMH of CAD s/p PCI 1983, CVA, GERD, HTN presented with retrosternal chest pain on 06/12 Associated dysphagia
More informationClinical Aspects of Multimodality Therapy for Resectable Locoregional Esophageal Cancer
Review Clinical Aspects of Multimodality Therapy for Resectable Locoregiol Esophageal Cancer Masayuki Shinoda, MD, Shunzo Hatooka, MD, Shoichi Mori, MD, and Tetsuya Mitsudomi, MD Radical resection has
More informationCase Scenario year-old white male presented to personal physician with dyspepsia with reflux.
Case Scenario 1 57-year-old white male presented to personal physician with dyspepsia with reflux. 7/12 EGD: In the gastroesophageal junction we found an exophytic tumor. The tumor occupies approximately
More informationMUSCLE-INVASIVE AND METASTATIC BLADDER CANCER
MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationMucosal Esophageal Squamous Cell Carcinoma With Intramural Gastric Metastasis Invading Liver and Pancreas: A Case Report
Int Surg 2014;99:458 462 DOI: 10.9738/INTSURG-D-13-00069.1 Case Report Mucosal Esophageal Squamous Cell Carcinoma With Intramural Gastric Metastasis Invading Liver and Pancreas: A Case Report Nobuhiro
More informationYuji Tachimori. Introduction
Review Article Pattern of lymph node metastases of squamous cell esophageal cancer based on the anatomical lymphatic drainage system: efficacy of lymph node dissection according to tumor location Yuji
More informationAdenocarcinoma of the gastroesophageal junction (GEJ) remains a neoplasia. Lymph node involvement in advanced gastroesophageal junction adenocarcinoma
General Thoracic Surgery Pedrazzani et al Lymph node involvement in advanced gastroesophageal junction adenocarcinoma Corrado Pedrazzani, MD, a Giovanni de Manzoni, MD, b Daniele Marrelli, MD, a Simone
More informationOverall survival analysis of neoadjuvant chemoradiotherapy and esophagectomy for esophageal cancer
Original Article Overall survival analysis of neoadjuvant chemoradiotherapy and esophagectomy for esophageal cancer Faisal A. Siddiqui 1, Katelyn M. Atkins 2, Brian S. Diggs 3, Charles R. Thomas Jr 1,
More informationDiagnosis and Surgical Outcomes for Primary Malignant Melanoma of the Esophagus: A Single-Center Experience
Diagnosis and Surgical Outcomes for Primary Malignant Melanoma of the Esophagus: A Single-Center Experience Shaohua Wang, MD, Yuji Tachimori, MD, Nobukazu Hokamura, MD, Hiroyasu Igaki, MD, Takayoshi Kishino,
More informationCharacteristics and pattern of recurrence after curative surgery in oesophageal cancer
1130-0108/2015/107/539-546 Revista Española de Enfermedades Digestivas Copyright 2015 Arán Ediciones, S. L. Rev Esp Enferm Dig (Madrid Vol. 107, N.º 9, pp. 539-546, 2015 ORIGINAL PAPERS Characteristics
More informationdoi: /j.ijrobp
doi:10.1016/j.ijrobp.2010.08.037 Int. J. Radiation Oncology Biol. Phys., Vol. 82, No. 1, pp. 475 482, 2012 Copyright Ó 2012 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/$ - see front
More informationThe Royal Marsden. Surgery for Gastric and GE Junction Cancer: primary palliative when and where? William Allum
The Royal Marsden Surgery for Gastric and GE Junction Cancer: primary palliative when and where? William Allum The Royal Marsden William Allum Conflict of Interest None Any surgeon can cure Surgeon - dependent
More informationPROPOSED REVISION OF THE STAGING CLASSIFICATION FOR ESOPHAGEAL CANCER
PROPOSED REVISION OF THE STAGING CLASSIFICATION FOR ESOPHAGEAL CANCER Robert J. Korst, MD a Valerie W. Rusch, MD a Ennapadam Venkatraman, PhD b Manjit S. Bains, MD a Michael E. Burt, MD, PhD a Robert J.
More informationLung cancer is a major cause of cancer deaths worldwide.
ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,
More informationPattern of lymphatic spread in thoracic esophageal squamous cell carcinoma: A single-institution experience
GENERAL THORACIC SURGERY Pattern of lymphatic spread in thoracic esophageal squamous cell carcinoma: A single-institution experience Bin Li, MD, a,b Haiquan Chen, MD, a,b Jiaqing Xiang, MD, a,b Yawei Zhang,
More informationOriginal articledote_1350. S. P. Mehta, 1 P. Jose, 1,2 A. Mirza, 3 S. A. Pritchard, 3 J. D. Hayden, 1 and H. I. Grabsch 2
1..7 Diseases of the Esophagus (2012), DOI: 10.1111/j.1442-2050.2012.01350.x Original articledote_1350 Comparison of the prognostic value of the 6th and 7th editions of the Union for International Cancer
More informationThe present staging system for esophageal carcinoma
Esophageal Carcinoma: Depth of Tumor Invasion Is Predictive of Regional Lymph Node Status Thomas W. Rice, MD, Gregory Zuccaro, Jr, MD, David J. Adelstein, MD, Lisa A. Rybicki, MS, Eugene H. Blackstone,
More informationCase presentation. Paul De Leyn, MD, PhD Thoracic Surgery University Hospitals Leuven Belgium
Case presentation Paul De Leyn, MD, PhD Thoracic Surgery University Hospitals Leuven Belgium Perspectives in Lung Cancer Brussels 6-7 march 2009 LEUVEN LUNG CANCER GROUP Department of Thoracic Surgery
More informationTreatment Strategy for Non-curative Resection of Early Gastric Cancer. Jun Haneg Lee. Sungkyunkwan University, Samsung Medical Center, Seoul Korea
Treatment Strategy for Non-curative Resection of Early Gastric Cancer Jun Haneg Lee. Sungkyunkwan University, Samsung Medical Center, Seoul Korea Classic EMR/ESD data analysis style Endoscopic resection
More informationWHO BENEFITS FROM ADJUVANT CHEMOTHERAPY RADIATION CHEMORADIATION? Dr. Paul Gardiner April 23, 2001 Discipline of Surgery Grand Rounds
WHO BENEFITS FROM ADJUVANT CHEMOTHERAPY RADIATION CHEMORADIATION? Dr. Paul Gardiner April 23, 2001 Discipline of Surgery Grand Rounds LUNG Dr. Greenland ESOPHAGUS Dr. Gardiner ESOPHAGEAL CANCER 1200 new
More informationAbstracting Upper GI Cancer Incidence and Treatment Data Quiz 1 Multiple Primary and Histologies Case 1 Final Pathology:
Abstracting Upper GI Cancer Incidence and Treatment Data Quiz 1 Multiple Primary and Histologies Case 1 A 74 year old male with a history of GERD presents complaining of dysphagia. An esophagogastroduodenoscopy
More informationJournal Annals of surgical oncology, 19(1): The final publication is available
A randomized trial comparing postop chemotherapy with cisplatin and 5-f Titleversus preoperative chemotherapy fo advanced squamous cell carcinoma of esophagus (JCOG9907) Ando, N; Kato, H; Igaki, H; Author(s)
More informationMINIMALLY INVASIVE ESOPHAGECTOMY FOR CANCER: where do we stand?
MINIMALLY INVASIVE ESOPHAGECTOMY FOR CANCER: where do we stand? Ph Nafteux, MD Copenhagen, Nov 3rd 2011 Department of Thoracic Surgery, University Hospitals Leuven, Belgium W. Coosemans, H. Decaluwé, Ph.
More informationMarcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP
Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIA* Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans
More informationComparison of the 6th and 7th Editions of the UICC-AJCC TNM Classification for Esophageal Cancer
Ann Surg Oncol (2012) 19:2142 2148 DOI 10.1245/s10434-012-2218-5 ORIGINAL ARTICLE THORACIC ONCOLOGY Comparison of the 6th and 7th Editions of the UICC-AJCC TNM Classification for Esophageal Cancer Koen
More informationChirurgie beim oligo-metastatischen NSCLC
24. Ärzte-Fortbildungskurs in Klinischer Onkologie 20.-22. Februar 2014, Kantonsspital St. Gallen Chirurgie beim oligo-metastatischen NSCLC Prof. Dr. med. Walter Weder Klinikdirektor Thoraxchirurgie, UniversitätsSpital
More informationSurgical Problems in Proximal GI Cancer Management Cardia Tumours Question #1: What are cardia tumours?
Surgical Problems in Proximal GI Cancer Management Cardia Tumours Question #1: What are cardia tumours? Question #2: How are cardia tumours managed? Michael F. Humer December 3, 2005 Vancouver, BC Case
More informationClinical Evaluation of Low-dose Cisplatin and 5-Fluorouracil as Adjuvant Chemoradiotherapy for Advanced Squamous Cell Carcinoma of the Esophagus
Hiroshima J. Med. Sci. Vol. 54, No. 3, 67-71, September, 25 HIJM54-11 67 Clinical Evaluation of Low-dose Cisplatin and 5-Fluorouracil as Adjuvant Chemoradiotherapy for Advanced Squamous Cell Carcinoma
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.
More informationSatisfactory surgical outcome of T2 gastric cancer after modified D2 lymphadenectomy
Original Article Satisfactory surgical outcome of T2 gastric cancer after modified D2 lymphadenectomy Shupeng Zhang 1, Liangliang Wu 2, Xiaona Wang 2, Xuewei Ding 2, Han Liang 2 1 Department of General
More informationItasu Ninomiya 1*, Koichi Okamoto 1, Tomoya Tsukada 1, Hiroto Saito 1, Sachio Fushida 1, Hiroko Ikeda 2 and Tetsuo Ohta 1
Ninomiya et al. Surgical Case Reports (2015) 1:25 DOI 10.1186/s40792-015-0030-8 CASE REPORT Open Access Thoracoscopic radical esophagectomy and laparoscopic transhiatal lymph node dissection for superficial
More informationWen-Bin Shen 1, Hong-Mei Gao 2, Shu-Chai Zhu 1*, You-Mei Li 1, Shu-Guang Li 1 and Jin-Rui Xu 1
Shen et al. World Journal of Surgical Oncology (2017) 15:192 DOI 10.1186/s12957-017-1259-4 RESEARCH Analysis of the causes of failure after radical surgery in patients with P T 3 N 0 M 0 thoracic esophageal
More informationHong-Yao Xu *, Sheng-Xi Wu, He-San Luo, Chu-Yun Chen, Lian-Xing Lin and He-Cheng Huang
Xu et al. Radiation Oncology (2018) 13:200 https://doi.org/10.1186/s13014-018-1145-4 RESEARCH Open Access Analysis of definitive chemo-radiotherapy for esophageal cancer with supra-clavicular node metastasis
More informationCharacteristics of intramural metastasis in gastric cancer. Tatsuya Hashimoto Kuniyoshi Arai Yuichi Yamashita Yoshiaki Iwasaki Tsunekazu
ORIGINAL ARTICLE Characteristics of intramural metastasis in gastric cancer Tatsuya Hashimoto Kuniyoshi Arai Yuichi Yamashita Yoshiaki Iwasaki Tsunekazu Hishima Author for correspondence: T. Hashimoto
More information